Gastrointestinal toxicities of proteasome inhibitor therapy.

ABSTRACT:

Purpose

Proteasome inhibitors (PIs), which cause cell death via tumor suppressor and pro-apoptotic proteins, are integral to treatment of many hematologic malignancies but are limited by their gastrointestinal adverse effects. Evidence regarding these PI-related adverse effects is scant. In this study, we evaluated gastrointestinal adverse events caused by PIs and compared gastrointestinal toxicities between bortezomib, carfilzomib, and ixazomib.

Methods

We conducted a retrospective study of cancer patients treated with PIs at a tertiary care cancer center to investigate the clinical characteristics of PI-related gastrointestinal adverse events.

Results

Our sample comprised 973 patients with PI exposure and stool studies ordered between January 2017 and December 2022.

SUBMITTER: Shah J 

PROVIDER: S-EPMC11226465 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature